| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Microbiology and Immunology, Indiana University School of Medicine, and Walther Cancer Institute, Indianapolis, IN 46202
Altering chromatin structure by blocking histone deacetylase activity with specific inhibitors such as trichostatin A can result in an up-regulation of gene expression. In this report, however, we show that expression of the ETS domain transcription factor PU.1 is down-regulated in cells following the addition of trichostatin A. The loss of PU.1 is seen at both the mRNA and protein levels in multiple cell lines and is reversible following removal of the drug. More importantly, we show that the loss of PU.1 results in a loss of PU.1 target gene expression, including CD11b, c-fms, Toll-like receptor 4, and scavenger receptor. Chromatin immunoprecipitation analysis of cells treated with trichostatin A showed a significant increase in the acetylation of histone H4, but not histone H3, across approximately 650 bp of the PU.1 promoter region. Our data suggest that the consequences of using drugs that inhibit histone deacetylase activity may be a loss of blood cell development and/or function due to a block in PU.1 gene expression.
This article has been cited by other articles:
|
|
 |
|
  L. Abramovitz, T. Shapira, I. Ben-Dror, V. Dror, L. Granot, T. Rousso, E. Landoy, L. Blau, G. Thiel, and L. Vardimon Dual Role of NRSF/REST in Activation and Repression of the Glucocorticoid Response J. Biol. Chem., January 4, 2008; 283(1): 110 - 119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Nencioni, J. Beck, D. Werth, F. Grunebach, F. Patrone, A. Ballestrero, and P. Brossart Histone Deacetylase Inhibitors Affect Dendritic Cell Differentiation and Immunogenicity Clin. Cancer Res., July 1, 2007; 13(13): 3933 - 3941. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G.-M. Zou, M.-H. Luo, A. Reed, M. R. Kelley, and M. C. Yoder Ape1 regulates hematopoietic differentiation of embryonic stem cells through its redox functional domain Blood, March 1, 2007; 109(5): 1917 - 1922. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nagel, M. Scherr, A. Kel, K. Hornischer, G. E. Crawford, M. Kaufmann, C. Meyer, H. G. Drexler, and R. A.F. MacLeod Activation of TLX3 and NKX2-5 in t(5;14)(q35;q32) T-Cell Acute Lymphoblastic Leukemia by Remote 3'-BCL11B Enhancers and Coregulation by PU.1 and HMGA1 Cancer Res., February 15, 2007; 67(4): 1461 - 1471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Brogdon, Y. Xu, S. J. Szabo, S. An, F. Buxton, D. Cohen, and Q. Huang Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function Blood, February 1, 2007; 109(3): 1123 - 1130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. T. Aung, K. Schroder, S. R. Himes, K. Brion, W. van Zuylen, A. Trieu, H. Suzuki, Y. Hayashizaki, D. A. Hume, M. J. Sweet, et al. LPS regulates proinflammatory gene expression in macrophages by altering histone deacetylase expression FASEB J, July 1, 2006; 20(9): 1315 - 1327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kitajima, M. Tanaka, J. Zheng, H. Yen, A. Sato, D. Sugiyama, H. Umehara, E. Sakai, and T. Nakano Redirecting differentiation of hematopoietic progenitors by a transcription factor, GATA-2 Blood, March 1, 2006; 107(5): 1857 - 1863. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-H. Choi, K.-H. Nam, J. Kim, M. W. Baek, J.-E. Park, H.-Y. Park, H. J. Kwon, O.-S. Kwon, D.-Y. Kim, and G. T. Oh Trichostatin A Exacerbates Atherosclerosis in Low Density Lipoprotein Receptor-Deficient Mice Arterioscler. Thromb. Vasc. Biol., November 1, 2005; 25(11): 2404 - 2409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. V. Pedchenko, G. Y. Park, M. Joo, T. S. Blackwell, and J. W. Christman Inducible binding of PU.1 and interacting proteins to the Toll-like receptor 4 promoter during endotoxemia Am J Physiol Lung Cell Mol Physiol, September 1, 2005; 289(3): L429 - L437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Frost, G. J. Nystrom, and C. H. Lang Epinephrine stimulates IL-6 expression in skeletal muscle and C2C12 myoblasts: role of c-Jun NH2-terminal kinase and histone deacetylase activity Am J Physiol Endocrinol Metab, May 1, 2004; 286(5): E809 - E817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rascle, J. A. Johnston, and B. Amati Deacetylase Activity Is Required for Recruitment of the Basal Transcription Machinery and Transactivation by STAT5 Mol. Cell. Biol., June 15, 2003; 23(12): 4162 - 4173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ferguson, P. A. Henry, and R. A. Currie Histone deacetylase inhibition is associated with transcriptional repression of the Hmga2 gene Nucleic Acids Res., June 15, 2003; 31(12): 3123 - 3133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Md. M. Rahman, A. Kukita, T. Kukita, T. Shobuike, T. Nakamura, and O. Kohashi Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages Blood, May 1, 2003; 101(9): 3451 - 3459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Musikacharoen, Y. Yoshikai, and T. Matsuguchi Histone Acetylation and Activation of cAMP-response Element-binding Protein Regulate Transcriptional Activation of MKP-M in Lipopolysaccharide-stimulated Macrophages J. Biol. Chem., March 7, 2003; 278(11): 9167 - 9175. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
